Merck & Co. Inc. (MRK)

89.19
NYSE : Health Technology
Prev Close 88.96
Day Low/High 88.44 / 89.59
52 Wk Low/High 70.89 / 89.96
Avg Volume 8.04M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 228.04B
EPS 2.30
P/E Ratio 41.77
Div & Yield 2.44 (2.47%)

Latest News

The Fed Today, What Could Go Wrong in December? Watching 4 Stocks: Market Recon

The Fed Today, What Could Go Wrong in December? Watching 4 Stocks: Market Recon

I do expect there to be some early to mid-December profit taking. But to get from here to year end without hitting some mid-month turbulence would be a pleasant surprise.

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.

Merck Might Make Healthy Rally

Merck Might Make Healthy Rally

Here's how to get in on the trade if it can hold on a pullback to the Oct. 22; also if Facebook's price holds above $186, expect it to go higher.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Despite the rhetoric from on high, it is possible to find good stock picks in this market.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Let's visit with the charts of MRK.

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

We don't have enough stock pickers or individuals to handle all the new stock that's been created. And It is trashing the cloud kings, among others.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Jim Cramer: The Market Is Lapping Up These Stocks

Jim Cramer: The Market Is Lapping Up These Stocks

There are plenty of senior growth companies that can still move higher.

Jim Cramer: What Would Make a Good Stock in This Environment?

Jim Cramer: What Would Make a Good Stock in This Environment?

Let me give you the items I want to see before I bless buying anything in what has become a plain, out and out, treacherous market.

Buying Merck? Here's the One Technical Level to Watch

Buying Merck? Here's the One Technical Level to Watch

The longer-term picture of MRK is positive.

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.

Merck Shares Could Trade Sideways Before Renewed Gains

Merck Shares Could Trade Sideways Before Renewed Gains

Let's visit with the charts and indicators to get another perspective.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

In my opinion, MA is a good one, otherwise it would not be on my book.

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

These three names - GD, MRK, WMT - will either hit resistance or hurdle immediate pivot points in as traders (or bots) try to form a technical breakout.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

A Bottoms Up Look at the Dow Industrials

A Bottoms Up Look at the Dow Industrials

Stock by stock checking on how many were in uptrends.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.